New drug duo aims to stop recurring bladder cancer
NCT ID NCT03258593
Summary
This early-stage study tested the safety of combining two drugs, Durvalumab and Vicineum, for people with a specific type of bladder cancer. The cancer was high-grade, had not spread into the bladder muscle, and had come back after standard BCG treatment. The goal was to see if this combination could help control the cancer and prevent it from returning or getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.